Biota Holdings
From Wikipedia, the free encyclopedia
Biota is an Australian antiviral drug development company listed on the Australian Stock Exchange (ASX:BTA).
In 1989 Biota discovered the drug Zanamivir, which acts as a neuraminidase inhibitor for the treatment and prevention of influenza. This drug is licensed to GlaxoSmithKline and marketed as Relenza. Zanamivir is currently being stockpiled by governments around the world in the wake of a possible avian influenza pandemic.
[edit] External links
 This article about an Australian corporation or company is a stub. You can help Wikipedia by expanding it. |
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
